Maintain vision and improve ocular health
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
![](https://www.nicox.com/wp-content/uploads/Nicox_optician.jpg)
The lead program of Nicox’s ophthalmic pipeline, NCX 470, is in Phase 3 clinical development targeting glaucoma. Our ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251. We have two products which are commercialized in the U.S.; VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively, and which are being rolled-out in territories outside of the U.S. through partnerships.